

EXECUTIVE SESSION

NOMINATION OF ROBERT LEON WILKINS TO BE UNITED STATES CIRCUIT JUDGE FOR THE DISTRICT OF COLUMBIA CIRCUIT

Mr. REID. Mr. President, I move to proceed to executive session to consider Calendar No. 381.

The PRESIDING OFFICER. The question is on agreeing to the motion to proceed.

The motion was agreed to.

The clerk will report the nomination.

The assistant legislative clerk read the nomination of Robert Leon Wilkins, of the District of Columbia, to be United States Circuit Judge for the District of Columbia Circuit.

CLOTURE MOTION

Mr. REID. Mr. President, I sent a cloture motion to the desk.

The PRESIDING OFFICER. The cloture motion having been presented under rule XXII, the Chair directs the clerk to read the motion.

The assistant legislative clerk read as follows:

CLOTURE MOTION

We, the undersigned Senators, in accordance with the provisions of rule XXII of the Standing Rules of the Senate, hereby move to bring to a close debate on the nomination of Robert Leon Wilkins, of the District of Columbia, to be United States Circuit Judge for the District of Columbia Circuit.

Harry Reid, Patrick J. Leahy, Tom Udall, Mark Begich, Brian Schatz, Al Franken, Barbara Boxer, Richard J. Durbin, Christopher A. Coons, Tammy Baldwin, Debbie Stabenow, Benjamin L. Cardin, Sheldon Whitehouse, Patty Murray, Barbara A. Mikulski, Kirsten E. Gillibrand, Tom Harkin.

Mr. REID. Mr. President, I ask unanimous consent the mandatory quorum under rule XXII be waived.

The PRESIDING OFFICER. Without objection, it is so ordered.

LEGISLATIVE SESSION

Mr. REID. Mr. President, I move to proceed to legislative session.

The PRESIDING OFFICER. The question is on agreeing to the motion. The motion was agreed to.

DRUG QUALITY AND SECURITY ACT—MOTION TO PROCEED—Continued

Mr. REID. If I understand, H.R. 3204 is now the pending matter.

The PRESIDING OFFICER. The Senator is correct.

CLOTURE MOTION

Mr. REID. Mr. President, I have a cloture motion with respect to the bill, which is at the desk.

The PRESIDING OFFICER. The cloture motion having been presented under rule XXII, the Chair directs the clerk to read the motion.

The assistant legislative clerk read as follows:

CLOTURE MOTION

We, the undersigned Senators, in accordance with the provisions of rule XXII of the

Standing Rules of the Senate, hereby move to bring to a close debate on H.R. 3204, an Act to amend the Federal Food, Drug, and Cosmetic Act with respect to human drug compounding and drug supply chain security, and for other purposes.

Harry Reid, Tom Harkin, Patrick J. Leahy, Jack Reed, Angus S. King, Jr., Mark Begich, Richard Blumenthal, Benjamin L. Cardin, Tim Kaine, Christopher A. Coons, Tom Udall, Sheldon Whitehouse, Joe Manchin III, Bill Nelson, Mark R. Warner, Debbie Stabenow, Amy Klobuchar.

Mr. REID. Mr. President, I ask unanimous consent the mandatory quorum under rule XXII be waived.

The PRESIDING OFFICER. Without objection, it is so ordered.

NATIONAL DEFENSE AUTHORIZATION ACT FOR FISCAL YEAR 2014—MOTION TO PROCEED

Mr. REID. Mr. President, I move to proceed to calendar No. 91, S. 1197.

The PRESIDING OFFICER. The clerk will report the bill by title.

The assistant legislative clerk read as follows:

The Senator from Nevada [Mr. REID] moves to proceed to consider Calendar No. 91, S. 1197, a bill to authorize appropriations for fiscal year 2014 for military activities of the Department of Defense, for military construction, and for defense activities of the Department of Energy, to prescribe military personnel strengths for such fiscal year, and for other purposes.

CLOTURE MOTION

Mr. REID. Mr. President, I have a cloture motion at the desk.

The PRESIDING OFFICER. The cloture motion having been presented under rule XXII, the Chair directs the clerk to read the motion.

The assistant legislative clerk read as follows:

CLOTURE MOTION

We, the undersigned Senators, in accordance with the provisions of rule XXII of the Standing Rules of the Senate, hereby move to bring to a close debate on the motion to proceed to Calendar No. 91, S. 1197, a bill to authorize appropriations for fiscal year 2014 for military activities of the Department of Defense, for military construction, and for defense activities of the Department of Energy, to prescribe military personnel strengths for such fiscal year, and for other purposes.

Harry Reid, Carl Levin, Jack Reed, Angus S. King, Jr., Mark Begich, Richard Blumenthal, Benjamin L. Cardin, Tim Kaine, Christopher A. Coons, Tom Udall, Sheldon Whitehouse, Bill Nelson, Joe Manchin III, Mark R. Warner, Debbie Stabenow, Amy Klobuchar, Richard J. Durbin.

Mr. REID. Mr. President, I ask unanimous consent that the mandatory quorum under rule XXII be waived.

The PRESIDING OFFICER. Without objection, it is so ordered.

MORNING BUSINESS

Mr. REID. Mr. President, I ask unanimous consent the Senate proceed to a period of morning business until 5 p.m. today with Senators permitted during

that time to speak for up to 10 minutes each.

The PRESIDING OFFICER. Without objection, it is so ordered.

The PRESIDING OFFICER. The Senator from Kansas.

DRUG QUALITY AND SECURITY ACT

Mr. ROBERTS. Mr. President, I come to the floor today to speak in support of the Drug Quality and Security Act, H.R. 3204. Getting this bill to where it is today—and I thank the leader for just making that possible, along with our minority leader—has been a long and sometimes very difficult road, one on which I have been working for over a decade—yes, 10 years.

This is an issue that hit far too close to home in Kansas. Several years ago, a pharmacist in Kansas City, Robert Courtney, was found to be diluting cancer drugs for his patients. Unfortunately, over 4,000 patients were affected before authorities could stop him. Senator Kit Bond at that time and myself worked together to hold the first Health, Education, Labor and Pensions Committee hearing on pharmacy compounding.

Since that time I have continued my interest in the compounding-related issues. Unfortunately, last September, over a year ago, the tragic meningitis outbreak began. This outbreak was the result of contaminated compounded medications produced by the New England Compounding Center.

Of the 751 people who became ill, 64 people lost their lives. Many of those who became ill are still suffering and have experienced painful relapses in their condition. Unfortunately, that is not the only occurrence in the last 10 years. Without proper safeguards and clear authority, I fear that these tragedies would only continue.

We acknowledged then that we had to buckle down and really get something done. Since that time, I have been working with my colleagues to draft the pending legislation before this body, the Drug Quality and Security Act, with the desire to protect patients and improve regulation of the pharmacy compounding industry.

I think that we have finally achieved what we all intended from the beginning, which is a bipartisan, bicameral product that is supported by a majority of the stakeholder groups and a variety of those groups. This legislation has the support of the pharmacists led by the National Community Pharmacists Association and the American Pharmacists Association. It has the support of the patient advocacy groups such as the Cancer Leadership Council and of industry groups such as the Pharmaceutical Distribution Security Alliance. In fact, this is quite a long list. I will not take the Senate's time to go over that list. But I would ask unanimous consent that this list be printed in the RECORD at this point in its entirety.